Pia Costea Selzer-Plon’s Post

Welcome to the world of pharmaceutical tendering: a high stakes game of strategy and skill, in which negotiators must navigate competitive bidding while adhering to diverse global regulations. Success relies on early and thorough preparation, astute market insight and smart pricing. JANE SIMON issues her prescription for mastering the art of risk prediction and positioning in this complex arena. To read Jane's article, click here 👉 bit.ly/4fIdTNB. #Negotiation #Pharma #Medtech #Tender

The The White House and U.S. Department of Health and Human Services (HHS) today announced the negotiated "maximum fair price" for the ten drugs selected for price negotiation in the first year of the #InflationReductionAct, which represent price reductions of 38-79% off list prices (before rebates). It is interesting that the CEOs of the companies that were engaged in these negotiations told shareholders in their second quarter earnings report that these reductions would have "limited" impact and could be effectively managed and reaffirmed optimistic projections for future growth. Is this an indicator for the degree of excess in drug prices? See our research on how the industry can effectively manage the drug price reductions under the IRA without reducing either their profits or innovation. https://lnkd.in/e8jJpgub Is this an indicator of how excessive drug prices have become? Center for Integration of Science and Industry at Bentley University Bentley University Center for Health and Business Institute for New Economic Thinking West Health #InflationReductionAct #Pharmaceutical #innovation

Don't miss the chance to register for our upcoming #webinar on the critical role of EU and UK #QualifiedPersons (#QPs) in navigating complex pharma #supplychains. Thermo Fisher Scientific experts Naomi Wilmer and Joris De Wolf will answer both pre-submitted and live questions about collaborating effectively with #QPs. Key highlights and takeaways will include: • Expectations and responsibilities of #UK and #EU QPs, plus collaboration strategies • Latest #regulatoryupdates and their impact on #pharmaceutical supply chains • Ensuring supply continuity across Europe, including QP oversight for UK imports • Key considerations for cold and frozen products, with a focus on #advancedtherapies • Practical insights for optimizing #QP collaboration and addressing key challenges Register here: http://spr.ly/6043mjqhB

In the latest issue of Supply Chain Management Review Magazine, US, the Editor-In-Chief of the magazine, Brian Straight, talks to Chandrachur Datta, Partner of Vector Consulting Group, on the challenges faced by the global pharma supply chain on this topic. Chandrachur has shared his views on challenges like volatile inventories due to dependency on imported materials, technological lag, and the balancing act between regulatory compliance and market demands. Read more https://lnkd.in/dzC9Z8cb   #Pharmaceutical #Resilience ##DestressToDeliver #Pharma #PharmaceuticalIndustry

Don't miss the chance to register for our upcoming #webinar on the critical role of EU and UK #QualifiedPersons (#QPs) in navigating complex pharma #supplychains. Thermo Fisher Scientific experts Naomi Wilmer and Joris De Wolf will answer both pre-submitted and live questions about collaborating effectively with #QPs. Key highlights and takeaways will include: • Expectations and responsibilities of #UK and #EU QPs, plus collaboration strategies • Latest #regulatoryupdates and their impact on #pharmaceutical supply chains • Ensuring supply continuity across Europe, including QP oversight for UK imports • Key considerations for cold and frozen products, with a focus on #advancedtherapies • Practical insights for optimizing #QP collaboration and addressing key challenges Register here: http://spr.ly/6044mjqh8

For #pharmaceutical companies considering expansion into the French market, the decision between obtaining #Exploitant status or inaugurating a regulatory office is pivotal.   Here is an overview: ➡ Exploitant Status: Allows market access without a physical footprint using a local partner's market insights. This path is less costly and facilitates faster entry but may reduce operational control and increase dependency on the partner. ➡ Regulatory Office: Establishes a direct market presence, ensuring complete operational control and enhancing brand visibility, albeit with higher initial costs and the challenge of complex regulatory navigation.   For personalised guidance on choosing the right strategy for your company's expansion into France, contact Elliogen today. Let us help you navigate your options for a successful market entry.   📨 hello@elliogen.com

🌐 Join us for a virtual Pharma Regulatory roundtable 🗓 Date: Thursday, 14 November 2024 🕟 Time: 4:30–5:30pm (CET) The life sciences sector is rapidly evolving. Staying informed about regulatory changes is crucial. Our roundtable will help you navigate the regulatory landscape and seize strategic opportunities. 🔗 Register today and ensure you don’t miss out on this valuable opportunity! https://lnkd.in/eyXVyJPq #Pharma #Regulatory #LifeSciences #VirtualRoundtable #IndustryInsights

Hope you and colleagues can join for this insightful free webinar on State Drug Price Transparency with Marbls and Novartis!

As a #pharmaceutical company, is your risk appetite clearly defined? Well it should! Because pharmaceutical companies in the USA, Europe, and Asia are facing increasing trade tensions and supply chain disruptions. For this reason, we see a trend toward decentralizing #manufacturing and #supplychains across the globe to enhance #resilience, #flexibility, and #responsiveness to local demands. But it all depends on your overall company risk appetite and the financial implications for your company. Discover our recommendations on how to secure supply in the face of current challenges. https://lnkd.in/eN2ne8F4 Stephan Fath Dr. Tim Femmer Peter Odenwälder Michelle Drew Rodriguez Michel JACOB Bernhard Langefeld Cristiano Sampaio Doria Axel Böhlke Erwin Douma Hauke Bossen Pol Busquets Luis Flavio Araujo Liang Quan Chris Ong Roland Berger

Upcoming Webinar on March 27th co-hosted by Marbls, Informa Connect Life Sciences, and Novartis! In collaboration with Novartis, Marbls is excited to invite you to a webinar on the Informa Connect Life Sciences platform. We’ll dive into the evolving legislative landscape of State Price Transparency Reporting and how it impacts pharmaceutical manufacturers. Join us as we delve into state requirements, the challenges they pose to manufacturers around data collection and the importance of maintaining compliance with each state entity. Agenda Highlights:  ·      Impacts of the latest legislation on your price reporting  ·      Trends in laws around PDABs and price increase triggers  ·      Challenges manufacturers face in data aggregation   ·      Advantages of introducing automation to your reporting practices If you’re interested in joining please reach out to Ritu Pandey for more details or let us know if you have any questions on price transparency reporting requirements. #lifesciences #pricing #contracting #sptr #statepricetransparency Arnab Sikder Ralph Lynn